Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers.

Ana Custodio, Jaime Feliu, Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Critical Reviews in Oncology Hematology. ,vol. 85, pp. 45- 81 ,(2013) , 10.1016/J.CRITREVONC.2012.05.001

Willi Sauerbrei, Martin Schumacher, A bootstrap resampling procedure for model building: Application to the cox regression model Statistics in Medicine. ,vol. 11, pp. 2093- 2109 ,(1992) , 10.1002/SIM.4780111607

F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685

Woo-Jeong Jeong, Pu-Hyeon Cha, Kang-Yell Choi, Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer World Journal of Gastroenterology. ,vol. 20, pp. 9862- 9871 ,(2014) , 10.3748/WJG.V20.I29.9862

Geraldine Perkins, Astrid Lièvre, Carole Ramacci, Tchao Méatchi, Aurélien de Reynies, Jean-François Emile, Valérie Boige, Gorana Tomasic, Jean-Baptiste Bachet, Fréderic Bibeau, Olivier Bouché, Frédérique Penault-Llorca, Jean-Louis Merlin, Pierre Laurent-Puig, Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. International Journal of Cancer. ,vol. 127, pp. 1321- 1331 ,(2010) , 10.1002/IJC.25152

Carsten Bokemeyer, Eric Van Cutsem, Philippe Rougier, Fortunato Ciardiello, Steffen Heeger, Michael Schlichting, Ilhan Celik, Claus-Henning Köhne, Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. European Journal of Cancer. ,vol. 48, pp. 1466- 1475 ,(2012) , 10.1016/J.EJCA.2012.02.057

Evangelia Razis, George Pentheroudakis, George Rigakos, Mattheos Bobos, George Kouvatseas, Olympia Tzaida, Thomas Makatsoris, Pavlos Papakostas, Maria Bai, Anna Goussia, Epaminontas Samantas, Demetrios Papamichael, Ourania Romanidou, Ioannis Efstratiou, Eleftheria Tsolaki, Amanda Psyrri, Wendy De Roock, Dimitrios Bafaloukos, George Klouvas, Sabine Tejpar, Konstantine T. Kalogeras, Dimitrios Pectasides, George Fountzilas, EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab Journal of Cancer Research and Clinical Oncology. ,vol. 140, pp. 737- 748 ,(2014) , 10.1007/S00432-014-1626-2

Rob Newbold, Mutant ras proteins and cell transformation Nature. ,vol. 310, pp. 628- 629 ,(1984) , 10.1038/310628A0

Ozlen Saglam, Christopher R. Garrett, David Boulware, Zena Sayegh, David Shibata, Mokenge Malafa, Timothy Yeatman, Jin Q. Cheng, Said Sebti, Domenico Coppola, Activation of the Serine/Threonine Protein Kinase AKT During the Progression of Colorectal Neoplasia Clinical Colorectal Cancer. ,vol. 6, pp. 652- 656 ,(2007) , 10.3816/CCC.2007.N.034

Ekta Agarwal, Anathbandhu Chaudhuri, Premila D Leiphrakpam, Katie L Haferbier, Michael G Brattain, Sanjib Chowdhury, Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer BMC Cancer. ,vol. 14, pp. 145- 145 ,(2014) , 10.1186/1471-2407-14-145